Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Dushyant Verma, Hagop Kantarjian, Sara S. Strom, Mary Beth Rios, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, Susan O'Brien, Jorge Cortes
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies'. Together they form a unique fingerprint.